The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1/2 OMAHA-01A substudy of oral CYP11A1 inhibitor opevesostat alone or in combination with other therapies for metastatic castration-resistant prostate cancer (mCRPC).
 
Arif Hussain
Consulting or Advisory Role - AstraZeneca (Inst); Bayer (Inst); Exelixis (Inst); Janssen Oncology (Inst)
Research Funding - AstraZeneca (Inst); Bayer (Inst); FutureChem (Inst); Merck (Inst); Orion (Inst); POINT Biopharma (Inst); Poseida Therapeutics (Inst); Regeneron (Inst)
 
Chris Garratt
Employment - Orion
Stock and Other Ownership Interests - Orion
 
Nan Li
Employment - Merck
 
Yingjie Liu
Employment - Merck
 
Christian Poehlein
Employment - Merck
Leadership - Merck
Stock and Other Ownership Interests - Merck
Travel, Accommodations, Expenses - Merck
 
Peter Fong
Consulting or Advisory Role - MSD